- Home
- Publications
- Publication Search
- Publication Details
Title
Trials and tribulations of pancreatic cancer immunotherapy
Authors
Keywords
Pancreatic cancer, Immunotherapy, Immune checkpoint inhibition, Tumor microenvironment, Tumor immunology
Journal
CANCER LETTERS
Volume 504, Issue -, Pages 1-14
Publisher
Elsevier BV
Online
2021-02-05
DOI
10.1016/j.canlet.2021.01.031
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tumor Cell–Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer
- (2020) Shipra Das et al. CANCER RESEARCH
- PCRT16-001: Phase II study of PEGPH20 plus pembrolizumab for patients (pts) with hyaluronan (HA)-high refractory metastatic pancreatic ductal adenocarcinoma (mPDA).
- (2020) E. Gabriela Chiorean et al. JOURNAL OF CLINICAL ONCOLOGY
- Fibroblast Heterogeneity in the Pancreatic Tumor Microenvironment
- (2020) Erin Helms et al. Cancer Discovery
- Regulatory T-cell Depletion Alters the Tumor Microenvironment and Accelerates Pancreatic Carcinogenesis
- (2020) Yaqing Zhang et al. Cancer Discovery
- Updated risk factors to inform early pancreatic cancer screening and identify high risk patients
- (2020) Daniel R. Principe et al. CANCER LETTERS
- Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I
- (2020) Keisuke Yamamoto et al. NATURE
- The m6A-Related mRNA Signature Predicts the Prognosis of Pancreatic Cancer Patients
- (2020) Zibo Meng et al. Molecular Therapy-Oncolytics
- IL-20 antagonist suppresses PD-L1 expression and prolongs survival in pancreatic cancer models
- (2020) Shao-Wei Lu et al. Nature Communications
- Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1
- (2019) Yu Pan et al. OncoImmunology
- Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer
- (2019) Jun Zhao et al. Nature Communications
- Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313
- (2019) Ramesh K. Ramanathan et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting Stroma: A Tale of Caution
- (2019) Andrea Wang-Gillam JOURNAL OF CLINICAL ONCOLOGY
- Phase I study of nivolumab (Nivo) + nab-paclitaxel (nab-P) + gemcitabine (Gem) in advanced pancreatic cancer (APC).
- (2019) Zev A. Wainberg et al. JOURNAL OF CLINICAL ONCOLOGY
- TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer
- (2019) Davide Melisi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A randomized Phase 2b study of GVAX pancreas and CRS-207 compared to chemotherapy in previously-treated metastatic pancreatic adenocarcinoma patients (ECLIPSE Study)
- (2019) Dung T. Le et al. CLINICAL CANCER RESEARCH
- A phase II study of ipilimumab and nivolumab with radiation in microsatellite stable (MSS) metastatic colorectal adenocarcinoma (mCRC).
- (2019) Aparna Raj Parikh et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase Ib dose-escalation and cohort-expansion study of safety and activity of the transforming growth factor (TGF) β receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.
- (2019) Davide Melisi et al. JOURNAL OF CLINICAL ONCOLOGY
- Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
- (2019) Ming Yi et al. Molecular Cancer
- TAMing pancreatic cancer: combat with a double edged sword
- (2019) Manendra Babu Lankadasari et al. Molecular Cancer
- The microbiota and microbiome in pancreatic cancer: more influential than expected
- (2019) Miao-Yan Wei et al. Molecular Cancer
- Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma
- (2019) Eileen M. O’Reilly et al. JAMA Oncology
- Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes
- (2019) Erick Riquelme et al. CELL
- Deciphering DNA methylation signatures of pancreatic cancer and pancreatitis
- (2019) Francesco Natale et al. Clinical Epigenetics
- 91O A multi-center phase IIa trial to assess the safety and efficacy of BL-8040 (a CXCR4 inhibitor) in combination with pembrolizumab and chemotherapy in patients with metastatic pancreatic adenocarcinoma (PDAC)
- (2019) M Hidalgo et al. ANNALS OF ONCOLOGY
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- Emerging epigenomic landscapes of pancreatic cancer in the era of precision medicine
- (2019) Gwen Lomberk et al. Nature Communications
- DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load
- (2019) Hyunchul Jung et al. Nature Communications
- Functions of N6-methyladenosine and its role in cancer
- (2019) Liuer He et al. Molecular Cancer
- The plasticity of pancreatic cancer metabolism in tumor progression and therapeutic resistance
- (2018) Douglas E. Biancur et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- T Cell Dysfunction in Cancer
- (2018) Daniela S. Thommen et al. CANCER CELL
- Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer
- (2018) Lydia Meder et al. CANCER RESEARCH
- Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations
- (2018) Zishuo I. Hu et al. CLINICAL CANCER RESEARCH
- Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
- (2018) Julius Strauss et al. CLINICAL CANCER RESEARCH
- Gut Microbiota Promotes Tumor Growth in Mice by Modulating Immune Response
- (2018) Vrishketan Sethi et al. GASTROENTEROLOGY
- Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape
- (2018) Max D. Wellenstein et al. IMMUNITY
- Dual TGF-β and PD-1 blockade synergistically enhances MAGE-A3-specific CD8+ T cell response in esophageal squamous cell carcinoma
- (2018) Xinfeng Chen et al. INTERNATIONAL JOURNAL OF CANCER
- Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment
- (2018) Suzanne Ostrand-Rosenberg et al. JOURNAL OF IMMUNOLOGY
- TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
- (2018) Daniele V. F. Tauriello et al. NATURE
- Understanding the tumor immune microenvironment (TIME) for effective therapy
- (2018) Mikhail Binnewies et al. NATURE MEDICINE
- The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
- (2018) Vyara Matson et al. SCIENCE
- MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma
- (2018) Scott J. Rodig et al. Science Translational Medicine
- Dual Transforming Growth Factor-β and Programmed Death-1 Blockade: A Strategy for Immune-Excluded Tumors?
- (2018) Claire Vanpouille-Box et al. TRENDS IN IMMUNOLOGY
- The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression
- (2018) Smruti Pushalkar et al. Cancer Discovery
- Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions
- (2018) Yifan Wang et al. Frontiers in Pharmacology
- Targeting VEGF/VEGFR to Modulate Antitumor Immunity
- (2018) Ju Yang et al. Frontiers in Immunology
- Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells
- (2018) A. M. Gravett et al. OncoImmunology
- Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
- (2018) Rikke B. Holmgaard et al. Journal for ImmunoTherapy of Cancer
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- Interplay between interferon regulatory factor 1 and BRD4 in the regulation of PD-L1 in pancreatic stellate cells
- (2018) Kazumi Ebine et al. Scientific Reports
- The Potential of CAR T Cell Therapy in Pancreatic Cancer
- (2018) Mehmet Akce et al. Frontiers in Immunology
- Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
- (2018) Davide Melisi et al. BRITISH JOURNAL OF CANCER
- Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression
- (2018) Christopher Groth et al. BRITISH JOURNAL OF CANCER
- Induction of MNK Kinase–dependent eIF4E Phosphorylation by Inhibitors Targeting BET Proteins Limits Efficacy of BET Inhibitors
- (2018) Thao N.D. Pham et al. MOLECULAR CANCER THERAPEUTICS
- TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell Mediated Regression of Pancreatic Cancer
- (2018) Daniel R Principe et al. MOLECULAR CANCER THERAPEUTICS
- Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade
- (2018) Jeffrey J. Ishizuka et al. NATURE
- Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells
- (2018) Hugh S. Gannon et al. Nature Communications
- Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
- (2017) Glen J. Weiss et al. INVESTIGATIONAL NEW DRUGS
- Phase I study of nivolumab (nivo) + nab-paclitaxel (nab-P) ± gemcitabine (Gem) in solid tumors: Interim results from the pancreatic cancer (PC) cohorts.
- (2017) Zev A. Wainberg et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase Ib/II pilot trial with nab-paclitaxel plus gemcitabine plus cisplatin in patients (pts) with stage IV pancreatic cancer.
- (2017) Gayle S. Jameson et al. JOURNAL OF CLINICAL ONCOLOGY
- The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion
- (2017) Chunwan Lu et al. JNCI-Journal of the National Cancer Institute
- Radiotherapy and immunotherapy: a beneficial liaison?
- (2017) Ralph R. Weichselbaum et al. Nature Reviews Clinical Oncology
- TGFβ engages MEK/ERK to differentially regulate benign and malignant pancreas cell function
- (2017) D R Principe et al. ONCOGENE
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Epigenetic plasticity and the hallmarks of cancer
- (2017) William A. Flavahan et al. SCIENCE
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- (2017) V. Gopalakrishnan et al. SCIENCE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
- (2017) Elizabeth Allen et al. Science Translational Medicine
- BET Proteins as Targets for Anticancer Treatment
- (2017) Anastasios Stathis et al. Cancer Discovery
- BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1
- (2017) Simon J. Hogg et al. Cell Reports
- The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion
- (2017) Chunwan Lu et al. JNCI-Journal of the National Cancer Institute
- TGF Signaling in the Pancreatic Tumor Microenvironment Promotes Fibrosis and Immune Evasion to Facilitate Tumorigenesis
- (2016) D. R. Principe et al. CANCER RESEARCH
- IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer
- (2016) Thomas A Mace et al. GUT
- Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?
- (2016) Elisabeth Hessmann et al. GUT
- Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib
- (2016) Pascal Hammel et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy
- (2016) Hong Jiang et al. NATURE MEDICINE
- T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
- (2016) Eric Tran et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting BET bromodomain proteins in solid tumors
- (2016) Vaibhav Sahai et al. Oncotarget
- Pancreatic cancer
- (2016) Jorg Kleeff et al. Nature Reviews Disease Primers
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
- (2015) Michael S. Rooney et al. CELL
- Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
- (2015) A. Patnaik et al. CLINICAL CANCER RESEARCH
- Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6Clow F4/80+ Extratumoral Macrophages
- (2015) Gregory L. Beatty et al. GASTROENTEROLOGY
- VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors
- (2015) Thibault Voron et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
- (2015) Christina Twyman-Saint Victor et al. NATURE
- Whole genomes redefine the mutational landscape of pancreatic cancer
- (2015) Nicola Waddell et al. NATURE
- Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma
- (2015) Pawel K Mazur et al. NATURE MEDICINE
- Targeting chromatin remodelling proteins to treat pancreatic cancer
- (2015) Hugh Thomas Nature Reviews Gastroenterology & Hepatology
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
- (2015) Leisha A. Emens et al. Cancer Immunology Research
- Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: importance of myeloid-derived suppressor cells
- (2015) Svetlana Karakhanova et al. OncoImmunology
- The antitumor immune response generated by fractionated radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade
- (2015) S J Dovedi et al. OncoImmunology
- A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer
- (2014) M. Aglietta et al. ANNALS OF ONCOLOGY
- The Role of Mechanical Forces in Tumor Growth and Therapy
- (2014) Rakesh K. Jain et al. Annual Review of Biomedical Engineering
- TGF- : Duality of Function Between Tumor Prevention and Carcinogenesis
- (2014) D. R. Principe et al. JNCI-Journal of the National Cancer Institute
- Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
- (2014) Gary Middleton et al. LANCET ONCOLOGY
- BET Bromodomain Inhibitors Block Growth of Pancreatic Cancer Cells in Three-Dimensional Collagen
- (2014) V. Sahai et al. MOLECULAR CANCER THERAPEUTICS
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Vaccine therapy for pancreatic cancer
- (2014) Bulent Salman et al. OncoImmunology
- Immunological Impact of Neoadjuvant Chemoradiotherapy in Patients with Borderline Resectable Pancreatic Ductal Adenocarcinoma
- (2013) Yuki Homma et al. ANNALS OF SURGICAL ONCOLOGY
- Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
- (2013) Jakob Lovén et al. CELL
- A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma
- (2013) G. L. Beatty et al. CLINICAL CANCER RESEARCH
- Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer
- (2013) Dung T. Le et al. JOURNAL OF IMMUNOTHERAPY
- Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels
- (2013) Vikash P. Chauhan et al. Nature Communications
- Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma
- (2012) Paolo P. Provenzano et al. CANCER CELL
- Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients
- (2012) Hidekazu Kameshima et al. CANCER SCIENCE
- Addition of Algenpantucel-L Immunotherapy to Standard Adjuvant Therapy for Pancreatic Cancer: a Phase 2 Study
- (2012) Jeffrey M. Hardacre et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
- (2012) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- An International Multicenter Randomized Controlled Trial of G17DT in Patients With Pancreatic Cancer
- (2012) Andrew D. Gilliam et al. PANCREAS
- A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma
- (2011) Lutz Eric et al. ANNALS OF SURGERY
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction
- (2011) D. T. Le et al. CLINICAL CANCER RESEARCH
- Pancreatic cancers require autophagy for tumor growth
- (2011) S. Yang et al. GENES & DEVELOPMENT
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical and Immunologic Evaluation of Dendritic Cell–Based Immunotherapy in Combination With Gemcitabine and/or S-1 in Patients With Advanced Pancreatic Carcinoma
- (2011) Yukino Kimura et al. PANCREAS
- CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
- (2011) G. L. Beatty et al. SCIENCE
- Targeting Mutated K-ras in Pancreatic Adenocarcinoma Using an Adjuvant Vaccine
- (2010) Ghassan K. Abou-Alfa et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Bacterial translocation and infected pancreatic necrosis in acute necrotizing pancreatitis derives from small bowel rather than from colon
- (2010) Stefan Fritz et al. AMERICAN JOURNAL OF SURGERY
- Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
- (2010) Richard E. Royal et al. JOURNAL OF IMMUNOTHERAPY
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses
- (2009) W M Liu et al. BRITISH JOURNAL OF CANCER
- Hypoxia stimulates pancreatic stellate cells to induce fibrosis and angiogenesis in pancreatic cancer
- (2008) Atsushi Masamune et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now